1. Pink Sheet

OSI DPP-IV Inhibitor Is A “Sensible Approach” To Diabetes Dosing, Firm Says

 
• By The Pink Sheet

The meal-related dosing schedule of OSI Pharmaceuticals' type 2 diabetes candidate PSN9301 could lead to better patient compliance, the company said

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet